Software as treatments

recent news:Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia Read more

Our Mission

Deliver safe and effective digital treatments to patients in need

We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments.

Science of Change

We are committed to helping you live the life you want. That is why we are developing the science of change. Our digital therapeutics empower you to alter the underlying mechanisms of disease—to target the thoughts, sensations, emotions and behaviors that define the experience of your condition—to help you achieve a healthier, happier life.

Our Collaborators

Otsuka

Otsuka and Click Therapeutics Launch $300 Million Collaboration to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder

Read More
Boehringer

Boehringer Ingelheim and Click Therapeutics Enter into $500 Million Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

Read More
Magellan

Magellan Health and Click Therapeutics Launch Fully Digital, Integrated and Comprehensive Smoking Cessation Program

Read More

Developing Software
As Treatments

We are a regulated Software as a Medical Device (SaMD)-focused biotechnology company that develops our applications as medical treatments in accordance with all relevant FDA, ISO and IEC standards.

01
Develop
We develop prescription software applications as medical devices that work independently or in conjunction with pharmacotherapies to treat disease.
02
Validate
We clinically validate these applications through rigorous randomized, controlled trials to demonstrate safety and efficacy.
03
Register
We seek FDA clearance for our apps as class II medical devices with independent therapeutic treatment claims or as adjuncts to existing therapy.
04
Commercialize
Physicians prescribe our apps and payers reimburse for them, while we generate and apply real world evidence to continuously personalize and improve the applications.

Leadership

David B. Klein
David B. Klein
Chief Executive Officer
Randall Stanicky
Randall Stanicky
Chief Financial Officer
Han Chiu
Han Chiu
Chief Technology Officer
Austin C. Speier
Austin C. Speier
Chief Strategy Officer
Shaheen Lakhan, MD, PhD, FAAN
Shaheen Lakhan, MD, PhD, FAAN
Chief Medical Officer
Richard DeNunzio
Richard DeNunzio
Chief Commercial Officer
Tarique Collins
Tarique Collins
Chief Legal Officer
Shanna Milford
Shanna Milford
Chief People Officer
view our team

In The News

Press2023-04-25
Click Therapeutics Initiates Fully Remote Pivotal Trial Using Investigational Prescription Digital Therapeutics to Treat Episodic Migraine
read more
Press2023-04-13
Click Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
read more
Press2022-03-28
Click Therapeutics Announces Formation of Scientific Advisory Board of Experts in Healthcare and Technology
read more
Press2022-03-10
Click Therapeutics Provides Research and Development Updates on Its Click Neurobehavioral Intervention (CNI) Platform
read more
Press2021-11-10
Click Therapeutics to Participate in the BTIG Digital Health Forum
read more
Press2021-10-22
Click Therapeutics Completes $52 Million Series B Financing Co-Led by H.I.G. BioHealth Partners and Accelmed Partners
read more
Press2021-04-07
Click Therapeutics Expands its Leadership with Executive and Board Appointments
read more
Press2021-03-09
Click Therapeutics Announces Collaboration with youturn to Expand Access to Clinically Validated Smoking Cessation Program Clickotine®
read more
Press2021-02-24
Otsuka and Click Therapeutics Initiate First-of-its-Kind Fully Remote Clinical Trial Using Digital Therapeutics as Adjunctive Therapy in Adults With Major Depressive Disorder
read more
Press2020-12-01
Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations
read more
Press2020-11-19
Click Therapeutics Announces that Solera Health will Provide Clinically Validated Smoking-Cessation Program Clickotine® to Blue Shield of California Members
read more
Press2020-09-11
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
read more
Press2020-05-11
Click Therapeutics Announces Participation in Upcoming Investor Conferences in May and June
read more
Press2020-04-23
Click Therapeutics Launches New Brand Identity and Redesigned Website
read more
Press2020-04-20
Magellan Health and Click Therapeutics Launch Fully Digital, Integrated and Comprehensive Smoking Cessation Program
read more
Press2020-02-24
Click Therapeutics to Present at the Cowen and Company 40th Annual Healthcare Conference
read more
Press2020-02-11
Click Therapeutics Announces Appointment of Top Healthcare Executives Muzammil Mansuri and Jeffrey Berkowitz as Senior Strategic Advisors and Formation of Payer Advisory Board
read more
Press2019-10-16
Click Therapeutics, Inc. Honored by Goldman Sachs for Entrepreneurship
read more
Press2019-09-04
Click Therapeutics Announces Appointment of Top Ranked Healthcare Research Analyst Ross J. Muken as Chief Financial Officer
read more
Press2019-01-03
Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder
read more
Press2018-10-02
Click Therapeutics Expands Executive Team with Chief Medical Officer and Chief Strategy Officer
read more
Press2018-07-23
Sanofi Ventures Leads $17 Million Financing of Click Therapeutics
read more
Press2018-06-06
Click Therapeutics Announces Multiple Publications Supporting Its Digital Therapeutic for Major Depressive Disorder; Seeking FDA Clearance
read more
Press2018-05-18
Click Therapeutics Awarded National Institutes of Health (NIH) Grant for Clickotine® Digital Therapeutic Study
read more
Press2018-02-14
Click Therapeutics Announces the Release of the Click Affective Pictures Set (CAPS) to Researchers Globally
read more
Press2017-04-25
Click Therapeutics Announces Multiple Publications of Clinical Data Supporting Digital Therapeutics™ Programs for Smoking Cessation and Major Depressive Disorder
read more
Press2017-03-20
Click Therapeutics Presents Data on Increased Efficacy of a Digital Therapeutics™ Program for Smoking Cessation at Six-Month Mark of Clinical Trial
read more
Press2016-09-21
Click Therapeutics™ Reports Preliminary Results of a 416-Participant Clinical Study Demonstrating Exceptional Engagement and Efficacy of Clickotine®, a Patent-Pending Digital Therapeutics™ Program for Smoking Cessation
read more

Contact us

Email us

Our offices
  • Headquarters
    80 White Street
    3rd Floor
    New York, NY 10013
  • 855 Boylston Street
    10th Floor
    Boston, MA 02116
  • 1111 Brickell Avenue
    10th Floor
    Miami, FL 33131
  • 1700 Montgomery Street
    Suite 108
    San Francisco, CA 94111

Cookies will improve your browsing experience. Would you like to accept the cookies?